摘要
目的探讨卡培他滨片化疗联合FOLFOX4方案治疗结肠癌患者的临床疗效及安全性。方法选取2018年6月至2020年6月在恩施土家族苗族自治州中心医院收治的80例结肠癌患者,按随机数字表法分治疗组与对照组,每组40例。对照组给予FOLFOX4方案治疗,治疗组在对照组的基础上加用卡培他滨片进行化疗。观察并比较两组患者治疗前后的免疫功能、血清细胞因子、肿瘤标志物、临床疗效及安全性的差异。结果治疗前,两组患者的免疫功能及血清细胞因子比较差异无统计学意义(P>0.05),治疗后,两组患者的免疫功能及血清细胞因子较治疗前均有明显改善,治疗组的CD8+明显低于对照组,而CD3^(+)、CD4^(+)、白细胞、血红蛋白、谷丙转氨酶明显高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的肿瘤标志物甲胎蛋白(CEA)、糖类抗原CA19-9、CA125比较差异无统计学意义(P>0.05);治疗后,两组CEA、CA19-9、CA125较治疗前均有明显改善,且治疗组明显低于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组的缓解率为90.0%,明显高于对照组的70.0%;而并发症发生率明显低于对照组(2.5%vs.20.0%),差异有统计学意义(P<0.05)。结论卡培他滨片化疗联合FOLFOX4方案对结肠癌患者的疗效较好,并且对免疫功能影响较小,用药更为方便安全,在临床治疗结肠癌方面具有一定的参考价值。
Objective To investigate the clinical efficacy and safety of patients with colon cancer before and after treatment with capecitabine tablets combined with FOLFOX4 regimen.Methods A total of 80 patients with colon cancer who were treated in our hospital from June 2018 to June 2020 were used as the prospective study objects,including 40 patients in the treatment group and 40 patients in the control group.Among them,the control group was given FOLFOX4 regimen treatment,and the treatment group was given capecitabine tablets chemotherapy on the basis of the control group.Observe and compare the differences in immune function,serum cytokines,tumor markers,clinical efficacy and safety of the two groups of patients before and after treatment.Results Before treatment,the immune function and serum cytokines of the two groups of patients were not statistically significant(P>0.05).After treatment,the immune function and serum cytokines of the two groups were significantly improved.The CD8+of the treatment group was significantly lower than that of the control group,while CD3+,CD4+,hemoglobin,alanine aminotransferase,and white blood cells were significantly higher than the control group.This difference was statistically significant(P<0.05).Before treatment,the comparison of tumor markers CEA,CA19-9 and CA125 between the two groups of patients showed no statistical significance(P>0.05);after treatment,the CEA,CA19-9 and CA125 of the two groups were significantly improved,and the tumor markers of the treatment group were significantly lower than those of the control group,statistics showed that this difference was significant(P<0.05).Analysis of clinical efficacy and complications after treatment showed that the remission rate of patients in the treatment group was 90.0%,significantly higher than that of the control group 70.0%,while the complication rate was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusions FOLFOX4 regimen combined with capecitabine tablet chemotherapy has better curative effect on patients with colon cancer,has less impact on immune function,and is more convenient and safe.It has a certain reference value in the clinical treatment of colon cancer.
作者
刘琨
王盈
邱珊
孙建华
邓璇
张靖
LIU Kun;WANG Ying;QIU Shan;SUN Jianhua;DENG Xuan;ZHANG Jing(Department of Colorectal and Anal Surgery,Enshi Tujia and Miao Autonomous Prefecture Central Hospital,Enshi 445000,China;Department of Oncology,Hubei Centre Hospital,Wuhan 434020,China)
出处
《中国肿瘤外科杂志》
CAS
2022年第1期69-72,共4页
Chinese Journal of Surgical Oncology
基金
湖北省卫生健康委2019年度第一批联合基金项目(WJ2019H127)。